Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Leukemia & Lymphoma|November 17, 2006
Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphomaMax Wolf, Mark Bentley, Paula Marlton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myelomaMark A Dawson, Stephen S Opat, Yamna Taouk, et al.
Haematologica|October 14, 2011
Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1Silvia C W Ling, Edwin K K Lau, Ammira Al-Shabeeb, et al.
BMC Medical Research Methodology|November 11, 2016
Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registryKrystal Bergin, Elizabeth Moore, Zoe McQuilten, et al.
Leukemia & Lymphoma|February 20, 2019
Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT studyNoemi Horvath, Andrew Spencer, Melita Kenealy, et al.
American Journal of Hematology|February 1, 2014
A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trialMark Hertzberg, Jane Palfrey Matthews, Janey Malka Stone, et al.
Cancer|May 19, 2016
Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myelomaRobert Z Orlowski, Arnon Nagler, Pieter Sonneveld, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 19, 2019
Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases RegistryP Joy Ho, Elizabeth M Moore, Zoe K McQuilten, et al.
Haematologica|October 14, 2011
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemiaHarry Iland, Ken Bradstock, John Seymour, et al.
Blood Advances|May 13, 2024
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16Peter Mollee, John Reynolds, Wojt Janowski, et al.
Pageof 3